News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
200 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (38485)
2025 (20956)
Month
January (3218)
February (3391)
March (3462)
April (3660)
May (4667)
June (3468)
July (2307)
August (2523)
September (2745)
October (3357)
November (3389)
December (2298)
Day
1 (200)
2 (82)
3 (2)
4 (4)
5 (170)
6 (196)
7 (173)
8 (142)
9 (54)
11 (3)
12 (130)
13 (197)
14 (170)
15 (163)
16 (65)
18 (3)
19 (32)
20 (217)
21 (197)
22 (203)
23 (65)
24 (3)
25 (4)
26 (180)
27 (242)
28 (255)
29 (239)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
11
12
13
14
15
16
18
19
20
21
22
23
24
25
26
27
28
29
Business
Michael Austwick Joins Verona Pharma as Non-Executive Director
Verona Pharma plc announces Mr. Michael Austwick has joined the board as a Non-Executive Director.
February 1, 2024
·
4 min read
Business
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024
Genflow Biosciences Plc is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.
February 1, 2024
·
6 min read
Business
EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO
EnteroBiotix Limited, a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, announced the appointments of Dr James Barnes as Chief Operating Officer and Chris Lea as Chief Financial Officer.
February 1, 2024
·
2 min read
Drug Development
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis
Bio-Thera Solutions announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis.
February 1, 2024
·
3 min read
Business
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Opthea Limited announced the appointment of Julie Clark, MD, MS, as Senior Vice President, Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024.
February 1, 2024
·
8 min read
Biotech Bay
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.
February 1, 2024
·
2 min read
BioForest
NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability
NanoString Technologies, Inc. announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry’s first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway.
February 1, 2024
·
7 min read
Business
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
Revvity, Inc., reported financial results for the fourth quarter and full year ended December 31, 2023.
February 1, 2024
·
32 min read
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 oral drug products has implications beyond COVID, setting the Company up for long term success and growth.
February 1, 2024
·
10 min read
Business
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023.
February 1, 2024
·
22 min read
Previous
2 of 20
Next